Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%

Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact

The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education

AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year

Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs

The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024

Moderna teams up with Recordati to commercialize rare disease therapy